>
Fa   |   Ar   |   En
   Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation  
   
نویسنده Eguchi Akiko ,Koyama Yukinori ,Wree Alexander ,Johnson Casey D. ,Nakamura Ryota ,Povero Davide ,Kneiber David ,Tameda Masahiko ,Contreras Patricia ,Spada Al ,Feldstein Ariel E.
منبع journal of molecular medicine - 2018 - دوره : 96 - شماره : 6 - صفحه:575 -583
چکیده    Development of portal hypertension (pht) is a central prognostic factor in patients with cirrhosis. circulating microparticles (mps) are released by hepatocytes in a caspase-dependent manner, are increased in circulation of patients with cirrhosis, and contribute to pht via induction of impaired vasoconstrictor responses. here, we tested the hypothesis that emricasan, a pan-caspase inhibitor, ameliorates pht and reduction in release of mps. we used a short-term and long-term protocol following common bile-duct ligation (bdl) in c57bl/6 mice (10 and 20 days, respectively). mice were treated daily via intraperitoneal injection with 10 mg/kg/day of emricasan or placebo. circulating mp levels were analyzed using flow cytometry and function via ex vivo angiogenesis assays. in contrast to bdl-placebo group, nearly all bdl-emricasan-treated mice survived after long-term bdl. assessment of portal pressure showed a significant increase in bdl-placebo mice compared to sham-placebo mice. in contrast, bdl-emricasan mice had significantly lower levels of portal pressure compared to bdl-placebo mice. although emricasan treatment resulted in a decrease in fibrosis, the changes did not reach statistical significance, suggesting that the effects on pht are at least in part independent of the anti-fibrotic effects of the drug. following short-term bdl, hepatocellular cell death as well as liver fibrosis had improved and circulating mps were significantly reduced in bdl-emricasan mice compared to bdl-placebo. circulating mps from bdl-placebo mice induced endothelial cell activation, and this was significantly reduced in mps from bdl-emricasan mice. our results indicate that emricasan treatment improves survival and pht in a murine model of long-term bdl. emricasan is a promising agent for the treatment of pht.
کلیدواژه Portal hypertension ,Cirrhosis ,Pan-caspase inhibitor ,Extracellular vesicles
آدرس University of California – San Diego, Department of Pediatrics, USA, University of California – San Diego, USA, University of California – San Diego, Department of Pediatrics, USA, University of California – San Diego, Department of Pediatrics, USA, University of California – San Diego, Department of Pediatrics, USA, University of California – San Diego, Department of Pediatrics, USA, University of California – San Diego, Department of Pediatrics, USA, University of California – San Diego, Department of Pediatrics, USA, Conatus Pharmaceuticals Inc., USA, Conatus Pharmaceuticals Inc., USA, University of California – San Diego, Department of Pediatrics, USA
 
     
   
Authors
  
 
 

Copyright 2023
Islamic World Science Citation Center
All Rights Reserved